Advertisement

Digestive Diseases and Sciences

, Volume 59, Issue 8, pp 1958–1965 | Cite as

Statin Use in Patients with Cirrhosis: A Retrospective Cohort Study

  • Sonal KumarEmail author
  • Norman D. Grace
  • Amir A. Qamar
Original Article

Abstract

Background

Statins reduce cardiovascular risk. Patients with cirrhosis have decreased hepatic clearance of statins and potentially increased risk for complications. No studies assess mortality in patients with biopsy-confirmed cirrhosis.

Aim

Compare mortality in patients with cirrhosis on statins to those not on statins.

Methods

A retrospective cohort study evaluated patients from 1988 to 2011 at Partners Healthcare Hospitals. The Partners Research Patient Data Registry identified patients with biopsy-proven cirrhosis on statins at biopsy and at least 3 months following. Controls were matched 1:2 by age, gender and Child–Pugh class. Decompensation was defined as ascites, jaundice/bilirubin >2.5 mg/dL, and/or hepatic encephalopathy or variceal hemorrhage. Primary outcome was mortality. Secondary outcome was decompensation in baseline-compensated patients. Chi-square and two-way ANOVA testing compared groups. Cox proportional hazards models for mortality controlled for age, Child–Pugh class, diabetes, coronary artery disease, non-alcoholic steatohepatitis and hepatocellular carcinoma. Kaplan–Meier curves graphed mortality.

Results

Eighty-one statin users and 162 controls were included. Median follow-up: 36 months in statin users and 30 months in controls. 70.4 % of patients were Child–Pugh A. Model for End-Stage Liver Disease (MELD), albumin, varices and beta-blocker use were not significantly different between groups. Statin users had lower mortality on multivariate analysis (HR 0.53, p = 0.01), and Child–Pugh A patients had longer survival on Kaplan–Meier analysis. Cox multivariate analysis for decompensation showed lower risk of decompensation with statins while increased decompensation with low albumin, high MELD score and beta-blocker use.

Conclusions

In patients with cirrhosis, statin therapy is not associated with increased mortality and may delay decompensation.

Keywords

Statins Cirrhosis Decompensation Child–Pugh 

Notes

Conflict of interest

None.

References

  1. 1.
    Targher G, Bertolini L, Padovani R, Rodella S, Acaro G, Day C. Differences and similarities in early atherosclerosis between patients with nonalcoholic steatohepatitis and chronic hepatitis B and C. J Hepatol. 2007;46:1126–1132.PubMedCrossRefGoogle Scholar
  2. 2.
    Longo M, Crosignani A, Battezzati PM, et al. Hyperlipidaemic state and cardiovascular risk in primary biliary cirrhosis. Gut. 2002;51:265–269.PubMedCentralPubMedCrossRefGoogle Scholar
  3. 3.
    Loria P, Lonardo A, Bellentani S, et al. Non-alcoholic fatty liver disease (NAFLD) and cardiovascular disease: an open question. Nutr Metab Cardiovasc Dis.. 2007;17:684–698.PubMedCrossRefGoogle Scholar
  4. 4.
    Kalaitzakis E, Rosengren A, Skommevik T, Bjornsson E. Coronary artery disease in patients with liver cirrhosis. Dig Dis Sci. 2010;55:467–475.PubMedCrossRefGoogle Scholar
  5. 5.
    Tiukinhoy-Laing SD, Rossi JS, Bayram M, et al. Cardiac hemodynamic and coronary angiographic characteristics of patients being evaluated for liver transplantation. Am J Cardiol. 2006;98:178–181.PubMedCrossRefGoogle Scholar
  6. 6.
    Raval Z, Harinstein ME, Skaro AI, et al. Cardiovascular risk assessment of the liver transplant candidate. J Am Coll Cardiol. 2011;58:223–231.PubMedCrossRefGoogle Scholar
  7. 7.
    Palmer SC, Craig JC, Navaneethan SD, Tonelli M, Pellegrini F, Strippoli GF. Benefits and harms of statin therapy for persons with chronic kidney disease: a systematic review and meta-analysis. Ann Intern Med. 2012;157:263–275.PubMedCentralPubMedCrossRefGoogle Scholar
  8. 8.
    Wiesbauer F, Heinze G, Mitterbauer C, Harnoncourt F, Horl WH, Oberbrauer R. Statin use is associated with prolonged survival of renal transplant recipients. J Am Soc Nephrol. 2008;19:2211–2218.PubMedCentralPubMedCrossRefGoogle Scholar
  9. 9.
    Frohlich GM, Rufiback K, Enseleit F, et al. Statins and the risk of cancer after heart transplantation. Circulation. 2012;126:440–447.PubMedCrossRefGoogle Scholar
  10. 10.
    Douglas I, Evans S, Smeeth L. Effect of statin treatment on short term mortality after pneumonia episode: cohort study. BMJ. 2011;42:1642.CrossRefGoogle Scholar
  11. 11.
    Poynter JN, Gruber SB, Higgins PDR, et al. Statins and the risk of colorectal cancer. N Engl J Med. 2005;352:2184–2192.PubMedCrossRefGoogle Scholar
  12. 12.
    Boudreau DM, Gardner JS, Malone KE, Heckbert SR, Blough DK, Daling JR. The association between 3-hydroxy-3-methylglutaryl coenzyme A inhibitor use and breast carcinoma risk among postmenopausal women: a case-control study. Cancer. 2004;100:2308–2316.PubMedCrossRefGoogle Scholar
  13. 13.
    Friis S, Poulsen AH, Johnsen SP, et al. Cancer risk among statin users: a population-based cohort study. Int J Cancer. 2005;114:643–647.PubMedCrossRefGoogle Scholar
  14. 14.
    Marcella SW, David A, Ohman-Strickland PA, Carson J, Rhoads GG. Statin use and fatal prostate cancer: a matched case-control study. Cancer. 2012;118:4046–4052.PubMedCrossRefGoogle Scholar
  15. 15.
    El-Serag HB, Johnson ML, Hachem C, Morgana RO. Statins are associated with a reduced risk of hepatocellular carcinoma in a large cohort of patients with diabetes. Gastroenterology. 2009;136:1601–1608.PubMedCentralPubMedCrossRefGoogle Scholar
  16. 16.
    Tsan YT, Lee CH, Wang JD, Chen PC. Statins and the risk of hepatocellular carcinoma in patients with hepatitis B virus infection. J Clin Oncol. 2012;30:623–630.PubMedCrossRefGoogle Scholar
  17. 17.
    Russo MW, Jacobson IM. How to use statins in patients with chronic liver disease. Cleve Clin J Med.. 2004;71:58–62.PubMedCrossRefGoogle Scholar
  18. 18.
    Stancu C, Sima A. Statins: mechanism of action and effects. J Cell Mol Med. 2001;5:378–387.PubMedCrossRefGoogle Scholar
  19. 19.
    Parra JL, Reddy KR. Hepatotoxicity of hypolipidemic drugs. Clin Liver Dis. 2003;7:415–433.PubMedCrossRefGoogle Scholar
  20. 20.
    Calderon RM, Cubeddu LX, Goldberg RB, Schiff ER. Statins in the treatment of dyslipidemia in the presence of elevated liver aminotransferase levels: a therapeutic dilemma. Mayo Clin Proc. 2010;85:349–356.PubMedCentralPubMedCrossRefGoogle Scholar
  21. 21.
    Argo CK, Loria P, Caldwell SH, Lonardo A. Statins in liver disease: a molehill, an iceberg or neither? Hepatology. 2008;48:662–669.PubMedCrossRefGoogle Scholar
  22. 22.
    Vuppalanchi R, Teal E, Chalasani N. Patients with elevated baseline liver enzymes do not have higher frequency of hepatotoxicity from lovastatin than those with normal liver enzymes. Am J Med Sci. 2005;329:62–65.PubMedCrossRefGoogle Scholar
  23. 23.
    Chalasani N. Statins and hepatotoxicity: focus on patients with fatty liver. Hepatology. 2005;41:690–695.PubMedCrossRefGoogle Scholar
  24. 24.
    Onofrei MD, Butler KL, Fuke DC, Miller HB. Safety of statin therapy in patients with preexisting liver disease. Pharmacotherapy.. 2008;28:522–529.PubMedCrossRefGoogle Scholar
  25. 25.
    Khorashadi S, Hasson NK, Cheung RC. Incidence of statin hepatotoxicity in patients with hepatitis C. Clin Gastroenterol Hepatol.. 2006;4:902–907.PubMedCrossRefGoogle Scholar
  26. 26.
    Chalasani N, Aljadhey H, Kesterson J, Murray MD, Hall SD. Patients with elevated liver enzymes are not at higher risk for statin hepatotoxicity. Gastroenterology. 2004;126:1287–1292.PubMedCrossRefGoogle Scholar
  27. 27.
    Lewis JH, Mortensen ME, Zweig S, et al. Efficacy and safety of high-dose pravastatin in hypercholesterolemic patients with well-compensated chronic liver disease: results of a prospective, randomized, double-blind, placebo-controlled, multicenter trial. Hepatology. 2007;46:1453–1463.PubMedCrossRefGoogle Scholar
  28. 28.
    Avins AL, Manos MM, Zhao W. Hepatic effects of lovastatin exposure in patients with liver disease. Drug Saf. 2008;31:325–334.PubMedCrossRefGoogle Scholar
  29. 29.
    Cohen DE, Anania FA, Chalasani N, National lipid association statin safety task force liver expert panel. An assessment of statin safety by hepatologists. Am J Cardiol. 2006;97:77C–81C.Google Scholar
  30. 30.
    Lewis JH. Clinical perspective: statins and the liver—harmful or helpful? Dig Dis Sci. 2012;57:1754–1763.PubMedCrossRefGoogle Scholar
  31. 31.
    Trebicka J, Hennenberg M, Laleman W, et al. Atorvastatin lowers portal pressures in cirrhotic rats by inhibition of RhoA/Rho-kinase and activation of endothelial nitric oxide synthase. Hepatology. 2007;46:242–253.PubMedCrossRefGoogle Scholar
  32. 32.
    Zafra C, Albrades JG, Turnes J, et al. Simvastatin enhances hepatic nitric oxide production and decreases the hepatic vascular tone in patients with cirrhosis. Gastroenterology. 2004;126:749–755.PubMedCrossRefGoogle Scholar
  33. 33.
    Albrades JG, Lapillus A, Banares R, et al. Simvastatin lowers portal pressure in patients with cirrhosis and portal hypertension: a randomized controlled trial. Gastroenterology. 2009;136:1651–1658.CrossRefGoogle Scholar
  34. 34.
    Morena M, Ramalho LN, Sancho-Bru P, et al. Atorvastatin attenuates angiotensin II-induced inflammatory actions in the liver. Am J Physiol Gastrointest Liver Physiol. 2009;296:G147–G156.CrossRefGoogle Scholar
  35. 35.
    Cholesterol Treatment Trialists’ (CTT) Collaborators, Kearney PM, Blackwell L et al. Efficacy of cholesterol lowering therapy in 18,686 people with diabetes in 14 randomised trials of statins: a meta-analysis. Lancet 2008;371:117–125.Google Scholar
  36. 36.
    Tonelli M, Lloyd A, Clement F, et al. Efficacy of statins for primary prevention in people at low cardiovascular risk: a meta-analysis. CMAJ. 2011;183:E1189–E1202.PubMedCentralPubMedCrossRefGoogle Scholar
  37. 37.
    Tsochatzis EA, Bosch J, Burroughs AK. Prolonging survival in patients with cirrhosis: old drugs with new indications. Gastroenterology. 2010;139:1813–1815.PubMedCrossRefGoogle Scholar
  38. 38.
    PDR Staff. Physicians’ desk reference. PDR Network; 2011.Google Scholar
  39. 39.
    Berzigotti A, Garcia-Tsao G, Bosch J, et al. Obesity is an independent risk factor for clinical decompensation in patients with cirrhosis. Hepatology. 2011;54:555–561.PubMedCentralPubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2014

Authors and Affiliations

  • Sonal Kumar
    • 1
    • 2
    Email author
  • Norman D. Grace
    • 1
  • Amir A. Qamar
    • 1
    • 3
  1. 1.Brigham and Women’s HospitalHarvard Medical SchoolBostonUSA
  2. 2.Weill Cornell Medical CollegeNew York Presbyterian HospitalNew YorkUSA
  3. 3.Lahey Hospital and Medical CenterBurlingtonUSA

Personalised recommendations